ONM 501
Alternative Names: ONM-501Latest Information Update: 03 Nov 2025
At a glance
- Originator University of Texas Southwestern Medical Center
- Developer OncoNano Medicine
- Class Antineoplastics; Immunotherapies; Polymers
- Mechanism of Action STING1 protein stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Lymphoma; Solid tumours
Most Recent Events
- 27 Oct 2025 Adverse events, pharmacodynamics and efficacy data from a phase I trial in Solid tumours and Lymphoma released by the OncoNano Medicine
- 22 Oct 2025 Efficacy and adverse events data from a phase I trial in Solid tumors and Lymphoma presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2025)
- 13 Oct 2023 Phase-I clinical trials in Lymphoma (Inoperable/Unresectable, Monotherapy, Second-line therapy or greater, Late-stage disease, Recurrent) in USA (Intratumoural) (NCT06022029)